Truist Securities Reiterates Buy on Caribou Biosciences, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a price target of $23.
July 14, 2023 | 4:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Caribou Biosciences has received a reiterated 'Buy' rating from Truist Securities with a maintained price target of $23.
The reiterated 'Buy' rating from Truist Securities indicates a positive outlook for Caribou Biosciences. The maintained price target of $23 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100